A Case of Malignant Lymphomas that Healed Completely After Oral Administrations of 4-Hydroxybenzaldehyde
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
In 1969, Mutsuyuki Kochi [1,2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and acquired its patent. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of the 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemia’s. Consequently, those who have these diseases can receive a considerably large dose of the medicine. The mechanism of action of the medicine is apparently competitive inhibition of tyrosine kinase, which is the rate-limiting enzyme in the pathway of carcinogenesis [3,4]. A 45-year-old woman (Y.Y.) visited the author’s clinic on August 7, 2014. She said that she had been diagnosed to have a malignant lymphoma of 3cm-diameter at the right side of her clavicular cavity and another one of 1cm-diameter at the right side of her neck at Mitsuhashi Gynecological Clinic in Kohriyama City, Nara Prefecture on June 20, 2014. At the author’s clinic, she was prescribed with daily 83mg (17ml of 5mg/ml aqueous solution) of 4-Hydroxybenzaldehyde during the period from August 8, 2014 until December 8, 2014. The daily dose was raised to 111mg (22ml of 5mg/ml aqueous solution) during the period from December 9, 2014 until March 8, 2015. The daily dose was raised to 167mg (33ml of 5mg/ml aqueous solution) during the period from March 9, 2015 to May 13, 2015. The daily dose was raised to 222mg (44ml of 5mg/ml aqueous solution) during the period from May 14, 2015 to August 11, 2015. The daily dose was raised to 333mg (67ml of 5mg/ml aqueous solution) during the period from August 12, 2015 to September 13, 2015.
Authors and Affiliations
Kimihiko Okazaki
Keywords
Related Articles
- EP ID EP587885
- DOI 10.32474/OAJOM.2018.01.000124
- Views 58
- Downloads 0
Quality of Life in Oncological Patient at the End of Life
Cancer is one of the diseases that have the greatest impact on the quality of life of its patients, either because of the real burden of the disease or because of all the myths involved in its diagnosis. The objective of...
Subjection between Breast Cancer and Body Mass Index, the Role of L-Carnitine in Prediction and Outcomes of the Disease
Increasing the effectiveness of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic antitumor therapy compared with patients receiving standard neoadjuvant systemic antitumor the...
Librarians who Request for Reprints Including those in Oncology
A 13-year retrospective study of reprint requestors was undertaken with special reference to those from research libraries. It was found that 2.8 percent of the total 2,053 requests were from such librarians. They prepon...
The Potential Role of Thioctic Acid in the Attenuation of Doxorubicin Induced-Cardiotoxicity
During 1950s in Italy a soil sample was isolated and found new strains of Streptomyces peucetius bacteria from which a new antibiotic was extracted with potent effect against murine tumors, this antibiotic named daunorub...
Thrombosis in Iron Deficiency and Iron Deficiency Anemia: A Review of our Cases and the Relevant Literature
We evaluated our thrombosis cases for iron deficiency (ID) or iron deficiency anemia (IDA) retrospectively and reviewed the literature. We established that iron parameters were studied in 17 of 64 patients with thrombosi...